Duration of Bare Sclera Pterygium Surgery Combined with Mitomycin C with and Without Tranexamic Acid: A Randomized Double-Blind Controlled Trial

<b><i>Purpose:</i></b> To evaluate the efficacy of subconjunctival tranexamic acid (TXA) in reducing intraoperative bleeding, shortening surgery duration, and improving postoperative outcomes in pterygium surgery. <b><i>Methods:</i></b> In this double-blind, randomized controlled trial, 50 eyes of 50 patients undergoing pterygium surgery were randomly assigned to receive either subconjunctival injection of 0.25 mL of 5% TXA (TXA group, <i>n</i> = 25) or an equivalent volume of saline (control group, <i>n</i> = 25). Baseline characteristics, including age, gender, working environment, allergies, preoperative logMAR best-corrected visual acuity, and systemic anticoagulant or antiplatelet therapy, were similar between the groups. The primary outcome measures were intraoperative bleeding, surgery duration, and the number of eye spears used. Secondary outcome measures included postoperative visual acuity and pterygium recurrence rates at 3 years post-surgery. <b><i>Results:</i></b> No significant differences were observed between the TXA group and the control group in terms of surgery duration (445.3 ± 94.8 s vs. 423.5 ± 80.6 s, <i>P</i> = 0.40), the number of eye spears used (3.5 ± 2.4 vs. 3.5 ± 2.6, <i>P</i> = 0.97), or the weight of absorbed blood (1.94 ± 1.40 grams vs. 1.90 ± 1.25 grams, <i>P</i> = 0.91). Additionally, there were no significant differences in postoperative visual acuity (0.14 ± 0.13 logMAR vs. 0.20 ± 0.19 logMAR, P = 0.39) or pterygium recurrence rates at 3 years post-surgery (8.0% vs. 4.4%, <i>P</i> = 0.60). Subconjunctival TXA injection was safe, with no reported adverse events or complications associated with its use. <b><i>Conclusion:</i></b> Subconjunctival injection of TXA did not significantly reduce intraoperative bleeding, shorten surgery duration, or improve postoperative outcomes in pterygium surgery. The intervention was safe and well-tolerated, but further research is warranted to explore alternative interventions or modifications to the surgical technique that may improve outcomes in pterygium surgery.

Authors

Institutions

Publication Details

Journal
Journal of Ocular Pharmacology and Therapeutics
Published
2024-11-20
DOI
https://doi.org/10.1089/jop.2024.0068
Citations
1
Primary Topic
Corneal Surgery and Treatments
Type
article
Field-Weighted Citation Impact
0.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Duration of Bare Sclera Pterygium Surgery Combined with Mitomycin C with and Without Tranexamic Acid: A Randomized Double-Blind Controlled Trial

Michael Mimouni, Yinon Shapira, Shmuel Graffi, Shadi Safuri et al.
1 citations
Journal of Ocular Pharmacology and Therapeutics
Corneal Surgery and Treatments
0.40
article

Duration of Bare Sclera Pterygium Surgery Combined with Mitomycin C with and Without Tranexamic Acid: A Randomized Double-Blind Controlled Trial

Michael Mimouni, Yinon Shapira, Shmuel Graffi, Shadi Safuri, Geulah S. Ben-David, Nevo Kovalis
article en
1 citations

Abstract

<b><i>Purpose:</i></b> To evaluate the efficacy of subconjunctival tranexamic acid (TXA) in reducing intraoperative bleeding, shortening surgery duration, and improving postoperative outcomes in pterygium surgery. <b><i>Methods:</i></b> In this double-blind, randomized controlled trial, 50 eyes of 50 patients undergoing pterygium surgery were randomly assigned to receive either subconjunctival injection of 0.25 mL of 5% TXA (TXA group, <i>n</i> = 25) or an equivalent volume of saline (control group, <i>n</i> = 25). Baseline characteristics, including age, gender, working environment, allergies, preoperative logMAR best-corrected visual acuity, and systemic anticoagulant or antiplatelet therapy, were similar between the groups. The primary outcome measures were intraoperative bleeding, surgery duration, and the number of eye spears used. Secondary outcome measures included postoperative visual acuity and pterygium recurrence rates at 3 years post-surgery. <b><i>Results:</i></b> No significant differences were observed between the TXA group and the control group in terms of surgery duration (445.3 ± 94.8 s vs. 423.5 ± 80.6 s, <i>P</i> = 0.40), the number of eye spears used (3.5 ± 2.4 vs. 3.5 ± 2.6, <i>P</i> = 0.97), or the weight of absorbed blood (1.94 ± 1.40 grams vs. 1.90 ± 1.25 grams, <i>P</i> = 0.91). Additionally, there were no significant differences in postoperative visual acuity (0.14 ± 0.13 logMAR vs. 0.20 ± 0.19 logMAR, P = 0.39) or pterygium recurrence rates at 3 years post-surgery (8.0% vs. 4.4%, <i>P</i> = 0.60). Subconjunctival TXA injection was safe, with no reported adverse events or complications associated with its use. <b><i>Conclusion:</i></b> Subconjunctival injection of TXA did not significantly reduce intraoperative bleeding, shorten surgery duration, or improve postoperative outcomes in pterygium surgery. The intervention was safe and well-tolerated, but further research is warranted to explore alternative interventions or modifications to the surgical technique that may improve outcomes in pterygium surgery.

Journal of Ocular Pharmacology and TherapeuticsVol. 40(10)
Technion – Israel Institute of Technology (IL), Rambam Health Care Campus (IL), Carmel Medical Center (IL)
Good health and well-being
Openalex Percentile: Top 33%
Corneal Surgery and Treatments
0.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.